Dr. Bekaii-Saab on Benefits Associated With Regorafenib for CRC

Tanios Bekaii-Saab, MD, associate professor, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, discusses the benefits patients receive with regorafenib for the treatment of colorectal cancer (CRC).

Though regorafenib and TAS-102 do not elicit partial or complete remissions, they do produce tumor shrinkage, Bekaii-Saab explains.

A study examined patients with lung metastases from the CORRECT trial, which investigated the efficacy of regorafenib versus placebo. With regorafenib, these tumors had a cavitation effect; cancer cells were killed without changing the size of the tumor. If patients have this lung cavitation, they will likely have tumor shrinkage and an improved progression-free survival, Bekaii-Saab says.